Immediate Impact
1 from Science/Nature 59 standout
Citing Papers
The interaction of innate immune and adaptive immune system
2024 Standout
An Update on the Nitrogen Heterocycle Compositions and Properties of U.S. FDA-Approved Pharmaceuticals (2013–2023)
2024 Standout
Works of Viola Klück being referenced
Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial
2020
P160 The first phase 2A proof-of-concept study of a selective NLRP3 inflammasome inhibitor, dapansutrile™ (OLT1177™), in acute gout
2019
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Viola Klück | 349 | 268 | 157 | 16 | 549 | |
| Camille Macé | 142 | 398 | 82 | 15 | 640 | |
| Toshiya Okumura | 162 | 125 | 136 | 16 | 494 | |
| Jianqiu Xiao | 494 | 112 | 191 | 22 | 605 | |
| Véronique Chobaz | 307 | 173 | 172 | 16 | 625 | |
| I Caorsi | 148 | 160 | 156 | 24 | 624 | |
| Y Thoua | 161 | 186 | 88 | 23 | 577 | |
| Ari M. Simckes | 216 | 203 | 178 | 16 | 632 | |
| Chongxu Shi | 234 | 148 | 115 | 17 | 544 | |
| Anita W.L. Tsang | 170 | 426 | 154 | 16 | 634 | |
| Robert L. Seigle | 189 | 354 | 76 | 13 | 582 |
All Works
Login with ORCID to disown or claim papers
Loading papers...